|
US7189834B2
(en)
*
|
1993-05-11 |
2007-03-13 |
Marshall William E |
Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection
|
|
US5849719A
(en)
*
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US7935675B1
(en)
*
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
GB2324093A
(en)
|
1996-01-04 |
1998-10-14 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
|
US20030078223A1
(en)
*
|
1996-01-30 |
2003-04-24 |
Eyal Raz |
Compositions and methods for modulating an immune response
|
|
ATE292980T1
(de)
|
1996-10-11 |
2005-04-15 |
Univ California |
Immunostimulierende oligonucleotidekonjugate
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
WO1998037919A1
(en)
|
1997-02-28 |
1998-09-03 |
University Of Iowa Research Foundation |
USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
|
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
|
EP1003531B1
(en)
|
1997-05-20 |
2007-08-22 |
Ottawa Health Research Institute |
Processes for preparing nucleic acid constructs
|
|
US20040006034A1
(en)
*
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
EP1003850B1
(en)
|
1997-06-06 |
2009-05-27 |
The Regents of the University of California |
Inhibitors of dna immunostimulatory sequence activity
|
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
US7138384B1
(en)
|
1997-08-29 |
2006-11-21 |
The Regents Of The University Of California |
Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
|
|
JP4663113B2
(ja)
*
|
1997-09-05 |
2011-03-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
|
|
GB9727262D0
(en)
*
|
1997-12-24 |
1998-02-25 |
Smithkline Beecham Biolog |
Vaccine
|
|
AU760549B2
(en)
|
1998-04-03 |
2003-05-15 |
University Of Iowa Research Foundation, The |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
|
JP2002514397A
(ja)
*
|
1998-05-14 |
2002-05-21 |
コーリー ファーマシューティカル ゲーエムベーハー |
ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
|
|
CA2330916C
(en)
|
1998-05-19 |
2011-04-05 |
Research Development Foundation |
Triterpene compositions and methods for use thereof
|
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
|
US6562798B1
(en)
*
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
|
PT1104306E
(pt)
|
1998-08-10 |
2006-05-31 |
Antigenics Inc |
Composicoes de cpg e adjuvantes de saponina e seus metodos
|
|
ATE326239T1
(de)
*
|
1998-09-18 |
2006-06-15 |
Dynavax Tech Corp |
Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
|
|
ES2572834T3
(es)
|
1999-02-17 |
2016-06-02 |
Csl Limited |
Complejos inmunogénicos y métodos relacionados con los mismos
|
|
EP1156781B1
(en)
|
1999-02-26 |
2005-06-08 |
Chiron Corporation |
Microemulsions with adsorbed macromolecules and microparticles
|
|
CA2371994C
(en)
|
1999-02-26 |
2010-09-28 |
Guido Grandi |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
|
|
EP1176966B1
(en)
*
|
1999-04-12 |
2013-04-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Oligodeoxynucleotide and its use to induce an immune response
|
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
PT1187629E
(pt)
|
1999-04-19 |
2005-02-28 |
Glaxosmithkline Biolog Sa |
Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
|
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
|
FR2797263B1
(fr)
*
|
1999-08-06 |
2003-09-19 |
Pasteur Merieux Serums Vacc |
Oligonucleotide immunostimulant
|
|
EP1196558A1
(fr)
*
|
1999-06-08 |
2002-04-17 |
Aventis Pasteur |
Oligonucleotide immunostimulant
|
|
AU5821000A
(en)
*
|
1999-06-29 |
2001-01-31 |
Smithkline Beecham Biologicals (Sa) |
Vaccine
|
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
|
US6514948B1
(en)
*
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
ATE419869T1
(de)
|
1999-08-19 |
2009-01-15 |
Dynavax Tech Corp |
Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
|
|
NZ517929A
(en)
*
|
1999-09-25 |
2004-02-27 |
Univ Iowa Res Found |
Immunostimulatory nucleic acids
|
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
|
CA2397374A1
(en)
*
|
2000-01-13 |
2001-07-19 |
Antigenics Inc. |
Innate immunity-stimulating compositions of cpg and saponin and methods thereof
|
|
AU2001227889A1
(en)
*
|
2000-01-14 |
2001-07-24 |
The United States of America, represented by The Secretary, Department of Health & Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
CA2398756A1
(en)
*
|
2000-01-31 |
2001-08-02 |
Eyal Raz |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
|
AU4175101A
(en)
|
2000-02-23 |
2001-09-03 |
Univ California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
|
EP1296714B1
(en)
|
2000-06-22 |
2009-08-26 |
University Of Iowa Research Foundation |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
WO2002002172A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Univ Jefferson |
Dna palindrome - oligoguanylic acid compositions and uses thereof
|
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
|
JP2005500806A
(ja)
*
|
2000-09-15 |
2005-01-13 |
コーリー ファーマシューティカル ゲーエムベーハー |
ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
|
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
|
ES2307568T3
(es)
*
|
2000-12-08 |
2008-12-01 |
Coley Pharmaceutical Gmbh |
Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
|
|
KR100881923B1
(ko)
*
|
2000-12-27 |
2009-02-04 |
다이나박스 테크놀로지 코퍼레이션 |
면역자극 폴리뉴클레오티드 및 그것의 사용 방법
|
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
|
WO2002094845A2
(en)
|
2001-05-21 |
2002-11-28 |
Intercell Ag |
Method for stabilising of nucleic acids
|
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
EP2423335B1
(en)
*
|
2001-06-21 |
2014-05-14 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same
|
|
SK15762003A3
(sk)
*
|
2001-06-29 |
2005-01-03 |
Chiron Corporation |
Kompozícia vakcíny HCV E1E2
|
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
|
US20030148316A1
(en)
*
|
2001-08-01 |
2003-08-07 |
Lipford Grayson B. |
Methods and compositions relating to plasmacytoid dendritic cells
|
|
US20030133988A1
(en)
*
|
2001-08-07 |
2003-07-17 |
Fearon Karen L. |
Immunomodulatory compositions, formulations, and methods for use thereof
|
|
WO2003020884A2
(en)
*
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
ATE411054T1
(de)
*
|
2001-08-17 |
2008-10-15 |
Coley Pharm Gmbh |
Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
|
|
JP4319908B2
(ja)
|
2001-08-24 |
2009-08-26 |
ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション |
プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
|
|
JP2005501917A
(ja)
*
|
2001-09-07 |
2005-01-20 |
ザ トラスティーズ オブ ボストン ユニバーシティ |
免疫複合体関連疾患を処置するための方法および組成物
|
|
DE60234375D1
(de)
|
2001-09-14 |
2009-12-24 |
Cytos Biotechnology Ag |
VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
|
|
WO2003027313A2
(en)
|
2001-09-24 |
2003-04-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
|
US20030119774A1
(en)
*
|
2001-09-25 |
2003-06-26 |
Marianna Foldvari |
Compositions and methods for stimulating an immune response
|
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
|
CN1633598A
(zh)
*
|
2001-10-05 |
2005-06-29 |
科勒制药股份公司 |
Toll样受体3信号传导的激动剂和拮抗剂
|
|
US20030139364A1
(en)
*
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
WO2003054161A2
(en)
|
2001-12-20 |
2003-07-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
|
EP3006043B1
(en)
*
|
2002-04-04 |
2019-05-29 |
Zoetis Belgium S.A. |
Immunostimulatory g,u-containing oligoribonucleotides
|
|
KR100456681B1
(ko)
*
|
2002-05-22 |
2004-11-10 |
주식회사 대웅 |
박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
|
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
|
US20040009949A1
(en)
*
|
2002-06-05 |
2004-01-15 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
|
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7569553B2
(en)
*
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
|
WO2004007743A2
(en)
*
|
2002-07-17 |
2004-01-22 |
Coley Pharmaceutical Gmbh |
Use of cpg nucleic acids in prion-disease
|
|
WO2004011650A2
(en)
|
2002-07-24 |
2004-02-05 |
Intercell Ag |
Antigens encoded by alternative reading frame from pathogenic viruses
|
|
EP1575504A4
(en)
*
|
2002-08-01 |
2009-11-04 |
Us Gov Health & Human Serv |
METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES
|
|
RU2338750C2
(ru)
*
|
2002-08-19 |
2008-11-20 |
Коли Фармасьютикал Груп, Инк. |
ИММУНОСТИМУЛИРУЮЩИЕ ФОСФОРТИОАТНЫЕ CpG-ОЛИГОНУКЛЕОТИДЫ, СОДЕРЖАЩИЕ ФОСФОДИЭФИРНЫЕ СВЯЗИ, СПОСОБ ИММУНОМОДУЛЯЦИИ, СПОСОБ СТИМУЛИРОВАНИЯ ИММУННОГО ОТВЕТА
|
|
AR040996A1
(es)
*
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
|
WO2004024182A2
(en)
|
2002-09-13 |
2004-03-25 |
Intercell Ag |
Method for isolating hepatitis c virus peptides
|
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
CN1753687A
(zh)
*
|
2002-10-29 |
2006-03-29 |
科勒制药集团股份有限公司 |
Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
|
|
WO2004098491A2
(en)
*
|
2002-11-01 |
2004-11-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
|
|
US20040248837A1
(en)
*
|
2002-11-01 |
2004-12-09 |
Eyal Raz |
Methods of treating pulmonary fibrotic disorders
|
|
EP1562982B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics S.r.l. |
Unexpected surface proteins in neisseria meningitidis
|
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
|
CA2502015A1
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5' cpg nucleic acids and methods of use
|
|
WO2004052293A2
(en)
*
|
2002-12-11 |
2004-06-24 |
Hawaii Biotech, Inc. |
Recombinant vaccine against flavivirus infection
|
|
JP5102959B2
(ja)
|
2002-12-23 |
2012-12-19 |
ダイナバックス テクノロジーズ コーポレイション |
免疫刺激配列オリゴヌクレオチド及びその使用方法
|
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
|
EP2263687B1
(en)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions containing phospholipid
|
|
EP1608402B1
(en)
|
2003-03-24 |
2010-10-20 |
Intercell AG |
Improved vaccines
|
|
AU2004226605A1
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
JP2007525177A
(ja)
|
2003-04-21 |
2007-09-06 |
アーケミックス コーポレイション |
血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
|
|
KR100872472B1
(ko)
*
|
2003-05-15 |
2008-12-05 |
도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 |
면역자극제
|
|
EP1633778B1
(en)
|
2003-06-05 |
2013-09-11 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli
|
|
MXPA05013922A
(es)
*
|
2003-06-20 |
2006-02-24 |
Coley Pharm Group Inc |
Antagonistas de receptor tipo toll de molecula pequena.
|
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
|
AU2004275876B2
(en)
*
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
|
EP1678303A2
(en)
*
|
2003-10-30 |
2006-07-12 |
Coley Pharmaceutical GmbH |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
|
US7973016B2
(en)
*
|
2004-01-23 |
2011-07-05 |
Joslin Diebetes Center |
Methods of treating, reducing, or preventing autoimmune conditions
|
|
JP2007526253A
(ja)
*
|
2004-02-19 |
2007-09-13 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
免疫刺激性ウイルスｒｎａオリゴヌクレオチド
|
|
WO2005086835A2
(en)
*
|
2004-03-05 |
2005-09-22 |
Archemix Corp. |
Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
|
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
|
US7579450B2
(en)
*
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
CN1989439B
(zh)
*
|
2004-05-06 |
2010-12-29 |
美国政府健康及人类服务部 |
治疗葡萄膜炎的方法以及组合物
|
|
US20060287263A1
(en)
*
|
2004-07-18 |
2006-12-21 |
Csl Limited |
Methods and compositions for inducing antigen-specific immune responses
|
|
EP2149583B1
(en)
|
2004-09-24 |
2015-10-28 |
Novartis AG |
Modified VP1-capsid protein of parvovirus B19
|
|
CA2587084C
(en)
|
2004-10-08 |
2019-07-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by using less frequently used synonym ous codons
|
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
|
EP2436391A3
(en)
|
2004-11-02 |
2012-07-04 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
WO2006081259A2
(en)
|
2005-01-27 |
2006-08-03 |
Children's Hospital & Research Center At Oakland |
Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
|
|
US20080009455A9
(en)
*
|
2005-02-24 |
2008-01-10 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
|
JP2008535859A
(ja)
*
|
2005-04-08 |
2008-09-04 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
感染症によって悪化した喘息を治療するための方法
|
|
AU2006241149A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
|
ATE502954T1
(de)
|
2005-06-14 |
2011-04-15 |
Protox Therapeutics Inc |
Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
CA2613442C
(en)
|
2005-06-30 |
2016-08-23 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
ATE439135T1
(de)
|
2005-07-01 |
2009-08-15 |
Index Pharmaceuticals Ab |
Modulierung der reaktion auf steroide
|
|
AU2006266503B2
(en)
|
2005-07-01 |
2011-12-08 |
Index Pharmaceuticals Ab |
Immunostimulatory method
|
|
KR20080030656A
(ko)
*
|
2005-07-07 |
2008-04-04 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
|
|
US20080206276A1
(en)
*
|
2005-07-08 |
2008-08-28 |
Michael Otto |
Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
|
|
CN101321868A
(zh)
*
|
2005-09-16 |
2008-12-10 |
科利制药公司 |
通过核苷酸修饰调节短干扰核糖核酸(siRNA)的免疫刺激特性
|
|
US20090214578A1
(en)
*
|
2005-09-16 |
2009-08-27 |
Coley Pharmaceutical Gmbh |
Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
|
|
US20070081972A1
(en)
*
|
2005-09-30 |
2007-04-12 |
The University Of Iowa Research Foundation |
Polymer-based delivery system for immunotherapy of cancer
|
|
AU2006306805A1
(en)
*
|
2005-10-28 |
2007-05-03 |
Index Pharmaceuticals Ab |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
|
JP4538522B2
(ja)
*
|
2005-11-25 |
2010-09-08 |
コーリー ファーマシューティカル ゲーエムベーハー |
免疫刺激性オリゴリボヌクレオチド
|
|
CA2636139A1
(en)
|
2005-12-14 |
2007-06-21 |
Cytos Biotechnology Ag |
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
|
|
DK2405002T3
(en)
|
2006-02-15 |
2015-01-05 |
Adiutide Pharmaceuticals Gmbh |
Compositions and methods for oligonukleotidformuleringer
|
|
EP2441469A1
(en)
|
2006-03-14 |
2012-04-18 |
Oregon Health and Science University |
Methods for producing an immune response to tuberculosis
|
|
EP2017281A4
(en)
|
2006-04-14 |
2012-03-14 |
Kyowa Hakko Kirin Co Ltd |
AGONISTS AT TOLL-LIKE RECEPTOR 9
|
|
US20070243290A1
(en)
*
|
2006-04-18 |
2007-10-18 |
Melody Thompson |
Method of tailoring infant formulas to individual nutritional needs prior to use
|
|
US8541559B2
(en)
|
2006-06-12 |
2013-09-24 |
Cytos Biotechnology Ag |
Process for producing aggregated oligonucleotides
|
|
PT2078080E
(pt)
|
2006-09-27 |
2015-09-18 |
Coley Pharm Gmbh |
Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
|
|
AU2007353120A1
(en)
*
|
2006-10-26 |
2008-11-20 |
Coley Pharmaceutical Gmbh |
Oligoribonucleotides and uses thereof
|
|
DK2444807T3
(da)
|
2006-11-01 |
2014-08-11 |
Ventana Med Syst Inc |
Mono- og dinitropyrazolhaptenkonjugater
|
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
|
WO2008106551A2
(en)
|
2007-02-28 |
2008-09-04 |
The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. |
Brachyury polypeptides and methods for use
|
|
WO2008131074A1
(en)
|
2007-04-19 |
2008-10-30 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
|
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
|
US8320302B2
(en)
|
2007-04-20 |
2012-11-27 |
Elster Electricity, Llc |
Over the air microcontroller flash memory updates
|
|
CA2687441A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Coley Pharmaceutical Group, Inc. |
Class a oligonucleotides with immunostimulatory potency
|
|
US9200287B2
(en)
*
|
2007-05-18 |
2015-12-01 |
Adiutide Pharmaceuticals Gmbh |
Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
|
|
EP2167963B1
(en)
|
2007-05-23 |
2019-04-17 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
WO2008147956A2
(en)
*
|
2007-05-25 |
2008-12-04 |
Centocor, Inc. |
Toll-like receptor 3 modulators and uses thereof
|
|
CN101820908A
(zh)
*
|
2007-10-09 |
2010-09-01 |
科利制药公司 |
包含改性糖部分的免疫刺激寡核苷酸类似物
|
|
EP2219671A4
(en)
|
2007-11-09 |
2011-02-09 |
Salk Inst For Biological Studi |
USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
|
|
EP3067048B1
(en)
|
2007-12-07 |
2018-02-14 |
GlaxoSmithKline Biologicals SA |
Compositions for inducing immune responses
|
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
|
WO2009143292A2
(en)
|
2008-05-21 |
2009-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
|
WO2009149013A2
(en)
|
2008-06-05 |
2009-12-10 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
|
ES2569907T3
(es)
|
2008-06-27 |
2016-05-13 |
Zoetis Services Llc |
Composiciones adyuvantes novedosas
|
|
JP2012503206A
(ja)
|
2008-09-22 |
2012-02-02 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
|
|
AU2009304552B2
(en)
|
2008-10-16 |
2015-02-19 |
Dalhousie University |
Combination adjuvant formulation
|
|
BRPI0922561A2
(pt)
|
2008-12-09 |
2020-08-11 |
Pfizer Vaccines Llc |
vacina de peptídeo de ch3 da ige.
|
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
|
CN103800906B
(zh)
|
2009-03-25 |
2017-09-22 |
德克萨斯大学系统董事会 |
用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
|
|
US20120052088A1
(en)
|
2009-04-30 |
2012-03-01 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
|
BRPI1012036A2
(pt)
|
2009-05-27 |
2017-10-10 |
Selecta Biosciences Inc |
nanocarreadores que possuem componentes com diferentes taxas de liberação
|
|
JP2013500326A
(ja)
|
2009-07-30 |
2013-01-07 |
ファイザー バクシーンズ エルエルシー |
抗原性タウペプチドおよびその使用
|
|
US8598327B2
(en)
|
2009-08-18 |
2013-12-03 |
Baxter International Inc. |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
|
JP2013502218A
(ja)
*
|
2009-08-18 |
2013-01-24 |
バクスター・インターナショナル・インコーポレイテッド |
組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
|
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
|
WO2011027257A2
(en)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
|
US8778683B2
(en)
|
2009-10-07 |
2014-07-15 |
Uvic Industry Partnerships Inc. |
Vaccines comprising heat-sensitive transgenes
|
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
|
CN102713629B
(zh)
|
2009-11-20 |
2016-02-24 |
俄勒冈健康科学大学 |
用于检测结核分枝杆菌感染的方法
|
|
RU2581020C2
(ru)
|
2009-12-22 |
2016-04-10 |
Селлдекс Терапьютикс, Инк. |
Композиции вакцин
|
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
|
TR201802933T4
(tr)
|
2010-03-30 |
2018-03-21 |
Childrens Hospital & Res Center At Oakland |
Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
|
|
TR201802741T4
(tr)
|
2010-05-14 |
2018-03-21 |
Univ Oregon Health & Science |
Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
|
|
CA2798739A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Nanocarrier compositions with uncoupled adjuvant
|
|
EP2575868A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
|
US8895017B2
(en)
|
2010-06-07 |
2014-11-25 |
Pfizer Inc. |
HER-2 peptides and vaccines
|
|
US8883171B2
(en)
|
2010-09-14 |
2014-11-11 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
|
EA201390660A1
(ru)
|
2010-11-05 |
2013-11-29 |
Селекта Байосайенсиз, Инк. |
Модифицированные никотиновые соединения и связанные способы
|
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
|
WO2012109675A1
(en)
|
2011-02-11 |
2012-08-16 |
Baxter International Inc. |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
|
US10941399B2
(en)
*
|
2011-04-14 |
2021-03-09 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
|
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
|
CA2837227C
(en)
|
2011-06-01 |
2022-05-10 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
|
WO2012167053A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
|
US9580475B2
(en)
|
2011-06-20 |
2017-02-28 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for H1N1 influenza
|
|
KR20140050698A
(ko)
|
2011-07-29 |
2014-04-29 |
셀렉타 바이오사이언시즈, 인크. |
체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
|
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
|
WO2013049535A2
(en)
|
2011-09-30 |
2013-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Influenza vaccine
|
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
|
EP3269728B1
(en)
|
2011-10-20 |
2020-12-16 |
The Government of The United States of America as represented by The Secretary, Department of Health and Human Services |
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
|
|
CA3208225A1
(en)
|
2012-01-16 |
2013-07-25 |
Elizabeth Mckenna |
Compositions and methods for the treatment of hepatitic diseases and disorders
|
|
US12268718B2
(en)
|
2012-01-16 |
2025-04-08 |
Labyrinth Holdings Llc |
Control of cellular redox levels
|
|
WO2013119683A1
(en)
|
2012-02-07 |
2013-08-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
|
|
CA2863949C
(en)
|
2012-02-13 |
2021-06-29 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
|
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
EP2852405B1
(en)
|
2012-05-23 |
2019-03-13 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
|
|
CN104428008B
(zh)
|
2012-05-24 |
2020-10-09 |
美国政府(由卫生和人类服务部的部长所代表) |
多价脑膜炎球菌缀合物及制备缀合物的方法
|
|
WO2013192144A2
(en)
|
2012-06-19 |
2013-12-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Rift valley fever virus replicon particles and use thereof
|
|
WO2014043518A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
|
JP2015535829A
(ja)
|
2012-09-21 |
2015-12-17 |
マッケーナ、エリザベス |
天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
|
|
WO2014052453A1
(en)
*
|
2012-09-25 |
2014-04-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
|
US20160083698A1
(en)
|
2013-04-19 |
2016-03-24 |
The Regents Of The University Of California |
Lone star virus
|
|
JP2016520077A
(ja)
|
2013-05-15 |
2016-07-11 |
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ |
Ｅ１ｅ２ｈｃｖワクチン及び使用方法
|
|
UA130246C2
(uk)
|
2013-09-19 |
2025-12-31 |
Зоетіс Сервісіз Ллс |
Ад'ювант на основі олії
|
|
ES2957209T3
(es)
|
2013-09-30 |
2024-01-15 |
Triad Nat Security Llc |
Polipéptidos inmunogénicos mosaicos del VIH de región conservada
|
|
WO2015063647A1
(en)
|
2013-11-01 |
2015-05-07 |
Pfizer Inc. |
Vectors for expression of prostate-associated antigens
|
|
JP6758185B2
(ja)
|
2013-12-13 |
2020-09-23 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
マルチエピトープｔａｒｐペプチドワクチンおよびその使用
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN110859957B
(zh)
|
2014-01-21 |
2024-04-12 |
辉瑞公司 |
包含缀合荚膜糖抗原的免疫原性组合物及其用途
|
|
BR112016015835B1
(pt)
|
2014-01-21 |
2023-12-26 |
Pfizer Inc |
Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
|
|
PL3096786T3
(pl)
|
2014-01-21 |
2021-11-08 |
Pfizer Inc. |
Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
|
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
|
CA2986096A1
(en)
|
2014-05-30 |
2015-12-03 |
Sanofi Pasteur Inc. |
Expression and conformational analysis of engineered influenza hemagglutinin
|
|
TR201908550T4
(tr)
|
2014-06-04 |
2019-07-22 |
Exicure Inc |
Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
|
|
EP3183251A4
(en)
|
2014-08-22 |
2017-12-27 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
|
HUE062499T2
(hu)
|
2015-01-15 |
2023-11-28 |
Pfizer |
Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
|
|
CN115317600A
(zh)
|
2015-01-16 |
2022-11-11 |
硕腾服务有限责任公司 |
口蹄疫疫苗
|
|
EP3256608A4
(en)
|
2015-02-13 |
2019-02-20 |
Icahn School of Medicine at Mount Sinai |
RNA CONTAINING COMPOSITIONS AND METHODS OF USE
|
|
AU2016270979B2
(en)
|
2015-06-02 |
2020-11-12 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
US10927151B2
(en)
|
2015-06-09 |
2021-02-23 |
Sanofi Pasteur Inc. |
Methods of optimizing nucleotide sequences encoding engineered influenza proteins
|
|
US10954492B2
(en)
|
2015-06-10 |
2021-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
WO2017011919A1
(en)
|
2015-07-22 |
2017-01-26 |
University Of Saskatchewan |
Mycoplasma vaccines and uses thereof
|
|
CN107921113A
(zh)
|
2015-08-25 |
2018-04-17 |
巴比塔·阿格拉沃尔 |
免疫调节组合物及其使用方法
|
|
EP3359651A1
(en)
|
2015-10-05 |
2018-08-15 |
THE UNITED STATES OF AMERICA, represented by the S |
Human rota virus g9p[6]strain and use as a vaccine
|
|
EP4491735A3
(en)
|
2015-10-08 |
2025-04-16 |
The Governors of the University of Alberta |
Hepatitis c virus e1/e2 heterodimers and methods of producing same
|
|
US11266726B2
(en)
|
2015-10-30 |
2022-03-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment of HER2-expressing solid tumors
|
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
|
MX2018008797A
(es)
|
2016-01-19 |
2018-11-29 |
Pfizer |
Vacunas contra el cancer.
|
|
WO2017189448A1
(en)
|
2016-04-25 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bivalent immunogenic conjugate for malaria and typhoid
|
|
EP3452598A4
(en)
|
2016-05-06 |
2020-04-29 |
Exicure, Inc. |
LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
|
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
|
CA3026096A1
(en)
|
2016-06-02 |
2017-12-07 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
|
EA201892385A1
(ru)
|
2016-06-03 |
2019-06-28 |
Санофи Пастер Инк. |
Модификация сконструированных полипептидов гемагглютинина вируса гриппа
|
|
US10947277B2
(en)
|
2016-06-13 |
2021-03-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
|
|
WO2018009603A1
(en)
|
2016-07-08 |
2018-01-11 |
The United State of America, as represented by the Secretary, Department of Health and Human Service |
Chimeric west nile/zika viruses and methods of use
|
|
BR112018077540A2
(pt)
|
2016-07-08 |
2019-10-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
|
|
CA3031797A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
CA3031799A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
US10172933B2
(en)
|
2016-10-31 |
2019-01-08 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Mosaic vaccines for serotype a foot-and-mouth disease virus
|
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
|
US11696954B2
(en)
|
2017-04-28 |
2023-07-11 |
Exicure Operating Company |
Synthesis of spherical nucleic acids using lipophilic moieties
|
|
WO2019018744A1
(en)
|
2017-07-21 |
2019-01-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
|
|
US11235046B2
(en)
|
2017-11-04 |
2022-02-01 |
Nevada Research & Innovation Corporation |
Immunogenic conjugates and methods of use thereof
|
|
WO2019126197A1
(en)
|
2017-12-18 |
2019-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacterial polysaccharide-conjugated carrier proteins and use thereof
|
|
JP2021506851A
(ja)
|
2017-12-19 |
2021-02-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
抗原−アジュバントカップリング試薬および使用の方法
|
|
CN111629751B
(zh)
|
2018-01-22 |
2025-02-21 |
美国政府(由卫生和人类服务部的部长所代表) |
广泛保护性灭活流感病毒疫苗
|
|
BR112020014978A2
(pt)
|
2018-02-05 |
2020-12-22 |
Sanofi Pasteur, Inc. |
Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
|
|
EP3749357A4
(en)
|
2018-02-05 |
2022-04-20 |
Sanofi Pasteur, Inc. |
POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
|
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
|
EP3774884B1
(en)
|
2018-03-28 |
2023-12-06 |
Sanofi Pasteur Inc. |
Methods of generating broadly protective vaccine compositions comprising hemagglutinin
|
|
JP2021519600A
(ja)
|
2018-04-03 |
2021-08-12 |
サノフイＳａｎｏｆｉ |
抗原性インフルエンザ−フェリチンポリペプチド
|
|
KR20210018205A
(ko)
|
2018-04-03 |
2021-02-17 |
사노피 |
항원성 OspA 폴리펩타이드
|
|
JP7614841B2
(ja)
|
2018-04-03 |
2025-01-16 |
サノフイ |
抗原性呼吸器合胞体ウイルスポリペプチド
|
|
EP3773698A1
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Ferritin proteins
|
|
WO2019195314A2
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic epstein barr virus polypeptides
|
|
WO2020014656A1
(en)
|
2018-07-13 |
2020-01-16 |
University Of Georgia Research Foundation |
Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
KR20210124205A
(ko)
|
2018-12-04 |
2021-10-14 |
더 락커펠러 유니버시티 |
Hiv 백신 면역원
|
|
WO2020123777A1
(en)
|
2018-12-12 |
2020-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
|
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
WO2020123989A1
(en)
|
2018-12-14 |
2020-06-18 |
University Of Georgia Research Foundation, Inc. |
Crimean-congo hemorrhagic fever virus replicon particles and use thereof
|
|
CN114957407A
(zh)
|
2019-04-02 |
2022-08-30 |
赛诺菲 |
抗原性多聚呼吸道合胞病毒多肽
|
|
WO2020208502A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
WO2021055580A2
(en)
|
2019-09-18 |
2021-03-25 |
Children's Medical Center Corporation |
An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
|
|
US20230000966A1
(en)
|
2019-11-01 |
2023-01-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
BR112022010228A2
(pt)
|
2019-12-17 |
2022-09-06 |
Us Health |
Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
|
|
BR112022014555A2
(pt)
|
2020-02-23 |
2022-09-20 |
Pfizer |
Composições de escherichia coli e métodos das mesmas.
|
|
US20230121059A1
(en)
|
2020-02-28 |
2023-04-20 |
Sanofi Pasteur Inc. |
High dose flu vaccine in pediatric subjects
|
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
|
BR112022021258A2
(pt)
|
2020-04-20 |
2023-01-17 |
Univ Saskatchewan |
Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
PE20231934A1
(es)
|
2020-10-27 |
2023-12-01 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas
|
|
CA3200602A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
JP7804673B2
(ja)
|
2020-11-10 |
2026-01-22 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
EP4243833A4
(en)
*
|
2020-11-13 |
2025-08-27 |
Guardian Therapeutics Llc |
GPC3 APTAMERS, VARIANTS AND RELATED USE
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
US20240299510A1
(en)
|
2020-12-31 |
2024-09-12 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
|
US20240159738A1
(en)
|
2021-03-16 |
2024-05-16 |
Osaka University |
Novel medical technique using follicular t-cells
|
|
US20240309051A1
(en)
|
2021-03-16 |
2024-09-19 |
Osaka University |
Follicular helper t (tfh) cells specific to sars-cov-2 virus
|
|
JP2024521847A
(ja)
|
2021-05-28 |
2024-06-04 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
|
WO2023288263A1
(en)
|
2021-07-16 |
2023-01-19 |
The Board Of Trustees Of The University Of Illinois |
Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
|
|
CN118176204A
(zh)
|
2021-08-11 |
2024-06-11 |
圣诺菲·帕斯图尔公司 |
截短的流感神经氨酸酶及其使用方法
|
|
AU2022361432A1
(en)
|
2021-10-08 |
2024-05-23 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines
|
|
AU2022379948A1
(en)
|
2021-11-05 |
2024-06-20 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
|
|
WO2023079113A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
|
|
MX2024005462A
(es)
|
2021-11-05 |
2024-05-22 |
Sanofi Sa |
Vacuna de arn del virus respiratorio sincitial.
|
|
MX2024006506A
(es)
|
2021-11-30 |
2024-08-14 |
Sanofi Pasteur Inc |
Vacunas basadas en vectores virales de metapneumovirus humano.
|
|
JP2024542635A
(ja)
|
2021-11-30 |
2024-11-15 |
サノフィ パスツール インコーポレイテッド |
ヒトメタニューモウイルスワクチン
|
|
JP2025500880A
(ja)
|
2021-12-17 |
2025-01-15 |
サノフイ |
ライム病ｒｎａワクチン
|
|
CA3247998A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
|
|
JP2025503207A
(ja)
|
2022-01-27 |
2025-01-30 |
サノフィ・パスツール |
修飾されたＶｅｒｏ細胞、及びウイルス産生にこれを使用する方法
|
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
|
EP4494146A1
(en)
|
2022-03-14 |
2025-01-22 |
Sanofi Pasteur, Inc. |
Machine-learning techniques in protein design for vaccine generation
|
|
CA3256624A1
(en)
|
2022-05-06 |
2023-11-09 |
Sanofi |
SIGNAL SEQUENCES FOR NUCLEIC ACID-BASED VACCINES
|
|
CA3256617A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
|
|
KR20250099727A
(ko)
|
2022-11-04 |
2025-07-02 |
사노피 파스퇴르 인크 |
호흡기 세포융합 바이러스 rna 백신접종
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
EP4622665A2
(en)
|
2022-11-22 |
2025-10-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AU2023403045A1
(en)
|
2022-12-01 |
2025-06-12 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
AU2023393199A1
(en)
|
2022-12-13 |
2025-05-29 |
Pfizer Inc. |
Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
|
|
EP4637813A1
(en)
|
2022-12-20 |
2025-10-29 |
Sanofi Pasteur |
Rhinovirus mrna vaccine
|
|
WO2024163327A1
(en)
|
2023-01-30 |
2024-08-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
|
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN120813371A
(zh)
|
2023-03-02 |
2025-10-17 |
赛诺菲巴斯德有限公司 |
用于在衣原体病的治疗中使用的组合物
|
|
PE20252774A1
(es)
|
2023-03-30 |
2025-12-22 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
|
|
AU2024255922A1
(en)
|
2023-04-14 |
2025-10-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
US12502424B2
(en)
|
2023-05-05 |
2025-12-23 |
Sanofi Pasteur Inc. |
Compositions for use in treatment of acne
|
|
WO2024231565A1
(en)
|
2023-05-10 |
2024-11-14 |
Sanofi |
Combination respiratory mrna vaccines
|
|
US20240398932A1
(en)
|
2023-05-11 |
2024-12-05 |
Sanofi Pasteur Inc. |
Respiratory syncytial virus vaccine and methods of use
|
|
KR20260015203A
(ko)
|
2023-05-19 |
2026-02-02 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
|
|
CN121620357A
(zh)
|
2023-06-01 |
2026-03-06 |
赛诺菲巴斯德有限公司 |
包含mRNA脂质纳米颗粒的热稳定组合物
|
|
EP4735028A1
(en)
|
2023-06-30 |
2026-05-06 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
|
|
AU2024291595A1
(en)
|
2023-07-19 |
2026-03-05 |
Sanofi |
Porphyromonas gingivalis antigenic constructs
|
|
WO2025051975A1
(en)
|
2023-09-06 |
2025-03-13 |
Sanofi |
Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
TW202527906A
(zh)
|
2023-09-14 |
2025-07-16 |
美商輝瑞股份有限公司 |
包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
|
|
TW202535439A
(zh)
|
2023-11-17 |
2025-09-16 |
美商賽諾菲巴斯德公司 |
海藻糖疫苗調配物
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025163460A2
(en)
|
2024-01-30 |
2025-08-07 |
Pfizer Inc. |
Vaccines against respiratory diseases
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025186459A1
(en)
|
2024-03-08 |
2025-09-12 |
Sanofi |
Antigenic epstein barr virus polypeptides
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|
|
WO2025238502A1
(en)
|
2024-05-14 |
2025-11-20 |
Pfizer Inc. |
Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
|
|
WO2025257712A1
(en)
|
2024-06-12 |
2025-12-18 |
Pfizer Inc. |
Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
|
|
EP4670733A1
(en)
|
2024-06-27 |
2025-12-31 |
Sanofi |
METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES
|
|
WO2026052773A1
(en)
|
2024-09-06 |
2026-03-12 |
Sanofi |
Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
|